Risk Assessment: BAUER LIFE SCIENCES LIMITED

1. Risk Rating: HIGH

Justification: The company is technically insolvent with net liabilities of £86,279 significantly exceeding total assets of £4,594. Cash reserves are virtually depleted at £89, and the company has demonstrated a persistent inability to generate positive shareholder funds across its entire 15-year operating history. The entity is entirely dependent on creditor forbearance—predominantly from directors or related parties—to continue as a going concern.

2. Key Concerns

Concern 1: Severe Insolvency and Going Concern Risk

The company has carried negative net assets every year for the decade of available records. Shareholders' funds have deteriorated from £-43,188 (2021) to £-86,379 (2025), with the 2025 position representing a near-doubling of deficits over four years. Current assets (£2,712) cover less than 3% of current liabilities (£90,873), indicating an extreme inability to meet obligations as they fall due. This is a textbook insolvent entity under both the balance sheet and cash flow tests defined in UK insolvency law.

Concern 2: Critical Liquidity Position

Cash at bank has declined from £303 (2024) to £89 (2025)—insufficient to cover even nominal administrative expenses. The company has no employees (NIL for both 2024 and 2025) and trade debtors of only £2,500, suggesting negligible trading activity. Without ongoing director or related-party funding, the company cannot sustain operations or meet its liabilities.

Concern 3: Opaque Creditor Structure and Related-Party Dependence

Of £90,873 in current liabilities, only £672 relates to trade creditors. The remaining £90,201 is classified as "other creditors," which almost certainly represents director loans or related-party advances. The accounts provide no breakdown or disclosure of these balances, their terms, or whether they are repayable on demand. This concentration of debt in a single opaque category, combined with the PSC (Mr Knight owning >75% of shares) also serving as director, creates significant related-party dependency risk.

3. Positive Indicators

• Regulatory Compliance Maintained: Accounts and confirmation statements are filed on time with no overdue filings. The company has not been flagged for any filing delinquency, which suggests ongoing administrative attention.
• Longevity of Operations: The company has been active since 2010 (15 years), indicating it has survived multiple financial cycles despite its insolvent position—likely through continued director support.
• Historical Improvement in Net Liabilities: Between 2016 and 2021, net liabilities improved from £-108,692 to £-43,188, suggesting the business had some capacity to reduce deficits during that period, even if the trend has since reversed.
• No Disqualification Records: Neither director appears on the Insolvency Service disqualification register, based on available data.

4. Due Diligence Notes

Priority Investigations:

1. Director Loan Accounts: Request full disclosure of the "other creditors" balance (£90,201). Determine whether these are director loans, whether they are interest-bearing, and crucially, whether they are repayable on demand or subordinated. If repayable on demand, the company could be forced into insolvency at any time.

2. Going Concern Basis: The accounts contain no explicit going concern statement or director assessment. Given the net liability position and near-zero cash, investigate whether directors have provided written commitments to continue financial support for at least 12 months from the reporting date—a critical requirement under FRS 102 Section 1A.

3. Trading Status and Revenue Generation: The company has zero employees and minimal trade debtors/creditors. Clarify whether the company is actively trading, in a development phase, or effectively dormant. If the latter, investigate whether dormant accounts would be more appropriate.

4. Intangible Assets History: The balance sheet shows fully amortised intangible assets of £105,000 (development costs capitalised then written off). Understand what this represented, whether it reflects a failed R&D programme, and whether any residual intellectual property value exists off-balance-sheet.

5. Related-Party Transactions: The accounts are filleted (no P&L filed) and audit-exempt. Request full related-party transaction disclosures, particularly any transactions between the company and Mr Knight or Mr Holder beyond the creditor balance.

6. Group Structure: Investigate whether either director has interests in other entities that interact with this company, particularly given the life sciences SIC code and the potential for IP licensing or inter-company arrangements.

7. Creditor Priority on Insolvency: If the company were to enter formal insolvency, determine the priority of claims. Director loans may rank behind other creditors if they are not secured, meaning directors could lose their investment entirely.